Evidence map›Paper›PMID 33912490›Full record

ArticleAdvanced biomedical research2020

Liver Function Tests Profile in COVID-19 Patients at the Admission Time: A Systematic Review of Literature and Conducted Researches.

Azadeh Laali, Alireza Tabibzadeh, Maryam Esghaei, Parastoo Yousefi, Saber Soltani, Hossein Ajdarkosh, Alireza Mosavi-Jarrahi, Mohamad Hadi Karbalaie Niya

Open access · goldAbstract read
In one paragraph

Article in Advanced biomedical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Azadeh LaaliDepartment of Infectious Diseases, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Alireza TabibzadehDepartment of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Maryam EsghaeiDepartment of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Parastoo YousefiDepartment of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Saber SoltaniDepartment of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Hossein AjdarkoshGastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
Alireza Mosavi-JarrahiSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohamad Hadi Karbalaie NiyaGastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.
Iran University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the start of coronavirus epidemic in Wuhan, China, in early December 2019, many literatures addressed its epidemiology, virology, and clinical presentation. In this review, we systematically reviewed the published literature in the field of liver function tests profile in COVID-19 patients at the admission time. MATERIALS AND

methodssystematic literature search were performed in EMBASE, PubMed, Science Direct, and Scopus using "severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2)", "SARS," "SARS-CoV," "coronavirus," "novel coronavirus," "liver," "hepatitis," "Liver function" keywords. The search was limited to range from 2019 to May 19, 2020.

resultsFrom a total 7298 articles, 145 were screened and 18 were eligible for further analysis. The highest rate of liver associated comorbidities was reported 11%. The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were the most frequent assessed enzymes. Increase in AST level was seen in 10%-53% of patients while The ALT increase was seen in 5%-28% of COVID-19 patients at the admission time. The prothrombin time was increase in 7%-12% of patients and the D-dimer was reports increase in 14%-36% of COVID-19 patients at the admission time. Furthermore, albumin decrease was seen in 6%-98% of COVID-19 patients at the admission time.

conclusionIn conclusion, by using the results of study, it could be suggested that the liver function tests assessment is critical assessment in COVID-19 patients at the admission time. This liver function test could be used as potential prognostic factor in COVID-19 severity in future.

Indexed as

COVID-19liverliver function testsSARS-CoV-2systematic review

Identifiers

PMID33912490
PMCPMC8059456
OpenAlexW3113928655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.